MT Newswires
UBS Adjusts Price Target on 10x Genomics to $20 From $14, Maintains Neutral Rating
➖
AI Sentiment
Neutral
5/10
- Home
- TXG
as of 02-26-2026 3:51pm EST
$21.98
+$2.32
+11.78%
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | PLEASANTON |
| Market Cap: | 2.8B | IPO Year: | 2019 |
| Target Price: | $16.82 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | 76.97 |
| 52 Week Low/High: | $6.78 - $23.56 | Next Earning Date: | 05-06-2026 |
| Revenue: | $245,893,000 | Revenue Growth: | 68.06% |
| Revenue Growth (this year): | -3.57% | Revenue Growth (next year): | 7.32% |
| P/E Ratio: | -56.17 | Index: | N/A |
| Free Cash Flow: | 130.1M | FCF Growth: | N/A |
AI-Powered TXG Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.81%
70.81%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of 10x Genomics Inc. (TXG)
Saxonov Serge
Sell
Chief Executive Officer
TXG Feb 23, 2026
Avg Cost/Share
$18.58
Shares
9,632
Total Value
$178,927.88
Owned After
1,061,924
SEC Form 4
Hindson Benjamin J.
Sell
See Remarks
TXG Feb 23, 2026
Avg Cost/Share
$18.58
Shares
7,826
Total Value
$145,378.91
Owned After
424,779
SEC Form 4
Taich Adam
Sell
Chief Financial Officer
TXG Feb 23, 2026
Avg Cost/Share
$18.58
Shares
8,968
Total Value
$166,593.16
Owned After
288,417
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Saxonov Serge | TXG | Chief Executive Officer | Feb 23, 2026 | Sell | $18.58 | 9,632 | $178,927.88 | 1,061,924 | |
| Hindson Benjamin J. | TXG | See Remarks | Feb 23, 2026 | Sell | $18.58 | 7,826 | $145,378.91 | 424,779 | |
| Taich Adam | TXG | Chief Financial Officer | Feb 23, 2026 | Sell | $18.58 | 8,968 | $166,593.16 | 288,417 |
Latest 10x Genomics Inc. News
TXG Breaking Stock News: Dive into TXG Ticker-Specific Updates for Smart Investing
Compare TXG vs Leading Stocks
See how TXG stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TXG 10x Genomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.